Moderna, Inc. (MRNA) Balance Sheet

The consistent reduction in total assets suggests that the company is consuming its accumulated pandemic wealth to fund ongoing operations and R&D. This downward trajectory warrants close monitoring, as it indicates that the firm's resource base is shrinking faster than it can be replenished by new commercial product revenue.

While the current ratio of 2.41 remains technically adequate, the rapid depletion of cash suggests that the company's runway is shortening significantly. Investors should consider whether this liquidity profile provides a sufficient cushion to withstand potential delays in the commercialization of the oncology and rare disease pipeline.

The sharp contraction in retained earnings highlights the impact of persistent negative net income on the company's book value. This trend suggests that the firm's internal capital generation is currently non-existent, forcing a reliance on existing equity to support its high-cost manufacturing and research infrastructure.

While the absolute debt level remains manageable, the upward trend in leverage during a period of revenue contraction may indicate a shift toward necessity-driven borrowing. This development warrants further investigation into the company's long-term ability to service these obligations if the commercial respiratory vaccine market fails to stabilize.